People

Saumya joined Eye2Gene as a Founder Associate around its commercial spinout, supporting strategy, governance, board/pitch materials, ISO work and communications. Its2026Part4staff introduction says she begins a Cambridge MPhil in Translating Medical Device and Advanced Therapy Research inOctober2026 and will remain part-time as Head of Communications; exacttransitionday is not invented. Her own public profile identifies Durham training and a2023–2024Weill Cornell ophthalmology research placement. The shareholder/manager name is not inferred from her communications role.